Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Proof-of-Concept Study of JNJ-67484703 in Moderate to Severe Atopic Dermatitis
2022-001528-14Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing JNJ-67484703 with Placebo (2 arms). Primary endpoint: EASI-75 response. Started Dec 2022; status: completed.
02
Drugs
JNJ-67484703
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-001528-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001528-14.